Johnson & Johnson news

   Watch this stock
Showing stories 1 - 10 of about 225   

Articles published

JNJ 142.40 +0.38 (0.27%)
price chart
Judge Tosses $417M Award Against Johnson & Johnson in Cancer Case
LOS ANGELES - A judge on Friday tossed out a $417 million jury award to a woman who claimed she developed ovarian cancer by using Johnson & Johnson talc-based baby powder for feminine hygiene. Los Angeles County Superior Court Judge Maren ...
California Judge Tosses $417 Million Talc Cancer Verdict Against Johnson ...  New York Times
Johnson & Johnson discards two hoped-for billion-dollar drugs
In May, Johnson & Johnson made a high-profile announcement of 11 “blockbuster potential” drugs that it planned to launch between 2017 and 2021.
J&J Fends Off Competition for Top Drug, Raises 2017 Forecast  Bloomberg
Johnson & Johnson's Q3, by the numbers  Motley Fool
Johnson & Johnson wins reversal of $72 million verdict over talc cancer risks
(Reuters) - Johnson & Johnson on Tuesday won the reversal of a $72 million verdict in favor of the family of a woman whose death from ovarian cancer they claimed stemmed from her use of the company's talc-based products like Johnson's Baby Powder.
Appeals court tosses $72 million award in Johnson & Johnson talcum ...  Chicago Tribune
Judge tosses $417M award against Johnson & Johnson
A judge on Friday, Oct. 20, 2017 tossed out a $417 million jury award to a woman who claimed she developed ovarian cancer by using Johnson & Johnson talc-based baby powder for feminine hygiene. Los Angeles County Superior Court Judge Maren ...
5 Key Drugs Critical to Johnson & Johnson's Future
Johnson & Johnson (NYSE:JNJ) recently shared its third-quarter financial report card with investors, and by all measures, it deserves kudos.
Johnson & Johnson: Create Your Own Dividends
Johnson & Johnson (JNJ) recently experienced a great combination of positive events. The company just reported a blowout Q3 earnings report, where revenue and earnings estimates were exceeded.
Healthcare ETFs in Focus on Johnson & Johnson Q3 Earnings  Yahoo Finance
Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2017  PR Newswire (press release)
Johnson & Johnson: Fully Priced As Operating Momentum Accelerates
Johnson & Johnson (JNJ) sees its share price trade at fresh highs following solid third quarter results, driven by the purchase of Actelion and solid operating performance.
Johnson & Johnson Outlook Buoyed by Drug Unit  Wall Street Journal
Can Johnson & Johnson build on this momentum?  Motley Fool
I Love Earnings Season! Let's See How Abbott Laboratories, Johnson & Johnson ...
I love earnings season. For a few weeks every three months, investors are given a look inside of a company's fundamentals to get a chance to see how the business is executing.
Johnson & Johnson earnings: All eyes on hurricane impact
When Johnson & Johnson reports third-quarter earnings, scheduled for Tuesday before the bell, investors will be closely watching for any commentary about the impact of three recent U.S.
Cramer Remix: Johnson & Johnson is out of battleground territory
"Mad Money" host Jim Cramer explains why the bulls are right and the stock of Johnson & Johnson is worth owning.